Novartis Starlix
Executive Summary
Nateglinide approved "as monotherapy, as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes" and as a concomitant therapy to diabetic agent metformin (Bristol's Glucophage), Novartis said. The firm is seeking a U.S. co-promotion partner; Merck KGaA will market the product in Europe. The NDA (21-204) was approved Dec. 22 and filed Dec. 17, 1999. Starlix is the 27th new molecular entity approved by FDA in 2000